REG - Imaging Biometrics - NOTICE OF ANNUAL GENERAL MEETING

Imaging BiometricsAnnouncement

12/05/2026 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260512:nRSL0280Ea&default-theme=true

RNS Number : 0280E  Imaging Biometrics Limited  12 May 2026

 

Imaging Biometrics Limited

("IBAI" or the "Company")

NOTICE OF ANNUAL GENERAL MEETING

 

Imaging Biometrics Limited, the Main Market listed healthcare technology
group, is pleased to announce that its Annual General Meeting ("AGM") will be
held at IFC5, St Helier, Jersey, JE1 1ST on 3 June 2026 at 10:00 am.

 

The Notice of AGM includes, inter alia, details of a proposed share
sub-division whereby each current ordinary share of £0.01 will be sub-divided
into one ordinary share of £0.0005. The number of ordinary shares in issue
will not change and will remain at 246,709,789 ordinary shares of £0.0005,
assuming that the sub-division resolution is passed at the AGM.

 

A form of proxy will accompany the Notice of AGM and the Noice of AGM will
shortly be available at https://imagingbiometrics.com/
(https://imagingbiometrics.com/)

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 For further information, please contact:

 

 Imaging Biometrics Limited

 Trevor Brown / Brett Skelly / Michael Schmainda / John Richardson

 Tel: 020 7469 0930
 AlbR Capital Limited (Corporate Broker)

 Lucy Williams / Duncan Vasey

 Tel: 020 7220 9797

 

 

Notes to Editors

About Imaging Biometrics Limited

Imaging Biometrics Limited is an LSE-listed healthcare technology group
focused on quantitative neuroimaging software and organ-on-a-chip technology.
Its principal subsidiary, Imaging Biometrics LLC, is a world leader in
advanced MRI analysis software used in the assessment of brain tumours, with
products distributed globally including through a commercial agreement with GE
HealthCare. Kirkstall Limited, acquired by IBAI in October 2025, develops the
Quasi Vivo® organ-on-a-chip platform for use in pharmaceutical research,
toxicology testing and disease modelling.

About Kirkstall Limited

Kirkstall Limited is a biotechnology company specialising in microfluidic
organ-on-a-chip systems. Its Quasi Vivo® platform enables cells to be
maintained under physiological flow conditions that closely mimic the human
body, providing pharmaceutical and academic researchers with more predictive
and human-relevant in vitro models. Kirkstall has an established international
distributor network spanning the United States, China and South Korea.

About Nottingham Trent University

NTU owns two Queen's Anniversary Prizes for outstanding achievements in
research (2015, 2021). The Research Excellence Framework (2021) classed 83% of
NTU's research activity as either world-leading or internationally excellent.
Professor Gareth Cave and his team in the School of Science and Technology
work at the interface of pharmaceutical science and biomedical engineering.

About the NC3Rs/BBSRC Business Interaction Voucher Scheme

The Business Interaction Voucher scheme is a joint funding initiative from the
NC3Rs and BBSRC designed to support collaboration between academic researchers
in the NC3Rs network and commercial partners. The scheme aims to accelerate
the development and adoption of human-relevant, animal-free research
technologies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUUUORNOUVAAR



            Copyright 2019 Regulatory News Service, all rights reserved